#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cytomegalovirus infection Lymphangiosarcoma Gestational trophoblastic tumour Thromboangiitis obliterans Hereditary spastic paraplegia Cholangiocarcinoma Hairy cell leukaemia recurrent Loss of consciousness Antiphospholipid antibodies Essential thrombocythaemia Lennox-Gastaut syndrome Congenital myopathy Glycogen storage disease type I Deafness neurosensory Langerhans' cell histiocytosis More trials…

    Learn about Rare Diseases

    Cystic fibrosis – Trials in Disease Angiosarcoma – Basic Information Idiopathic pulmonary fibrosis Mucous membrane pemphigoid – Basic Information Cystic fibrosis – Basic Information Mantle cell lymphoma – Treatment Myelodysplastic syndrome with excess blasts – Life with Disease Phenylketonuria – Life with Disease Congenital generalised lipodystrophy – Treatment Haemophilia A without inhibitors – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Thiamazole Lebrikizumab Siponimod Nvdx3 Iron Loncastuximab Tesirine Octocog Alfa Avacopan ANTI-GD2-800CW Fludarabine Phosphate Indacaterol Lifileucel Specific Nucleic Acid Sna-Veru GSKVX000000070250 Mbf-015 Erenumab ZILEBESIRAN RNK001 Carbasalate Calcium Iberdomide More therapies…

    Learn about Your Condition

    Monogenic diabetes Glanzmann's disease Subdural haematoma Hip arthroplasty Advanced systemic mastocytosis Myeloid leukaemia Plasma cell leukaemia Haemofiltration Thymoma malignant Prodromal Alzheimer's disease Diabetic ketoacidosis Eye inflammation Optic glioma Uveal melanoma Ovarian cancer stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Azienda Sanitaria Universitaria Giuliano Isontina

Azienda Sanitaria Universitaria Giuliano Isontina

Strada Di Fiume 447, Trieste, 34149, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment

    Recruiting

    3 1 1
    Investigated Drugs:
    • Rilzabrutinib
    Austria Czechia France Germany Hungary Italy +3

  • A study of LTP001 in combination with standard treatment for adults with pulmonary arterial hypertension

    Recruiting

    1 1
    Investigated Diseases:
    • Pulmonary arterial hypertension
    Investigated Drugs:
    • Ltp001
    Belgium Czechia France Germany Greece Italy +6

  • Study of felzartamab compared to placebo in adults with IgA nephropathy

    Recruiting

    3 1 1
    Investigated Drugs:
    • Fexofenadine
    • Felzartamab
    • Desloratadine
    Belgium Bulgaria Croatia Czechia France Germany +5

  • Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hypertension
    • Type 2 diabetes mellitus
    • Cardiovascular disorder
    Investigated Drugs:
    • Bi 690517
    • Empagliflozin
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study of Atacicept Treatment for Patients with Multiple Autoimmune Glomerular Diseases

    Recruiting

    2 1 1
    Investigated Drugs:
    • Atacicept
    Belgium France Germany Italy Poland Spain

  • Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

    Recruiting

    3 1
    Investigated Diseases:
    • Autoimmune haemolytic anaemia
    Investigated Drugs:
    • Rilzabrutinib
    Austria Czechia Denmark Germany Greece Hungary +6

  • Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Anidulafungin
    • Caspofungin Acetate
    • FOSMANOGEPIX
    Austria Belgium France Germany Greece Italy +2

  • Study on the Safety and Effectiveness of Pirtobrutinib for Adults with Immune Thrombocytopenia

    Recruiting

    1 1
    Investigated Diseases:
    • Immune thrombocytopenia
    Investigated Drugs:
    • Pirtobrutinib
    Denmark France Italy Norway Poland Spain

  • Study on the Effectiveness and Safety of Human Normal Immunoglobulin (IV) for Adults with Chronic Immune Thrombocytopenia

    Recruiting

    3 1 1
    Investigated Diseases:
    • Thrombocytopenia
    Investigated Drugs:
    • Human Normal Immunoglobulin (Iv)
    Czechia Germany Italy Romania Spain

  • Study on the Effectiveness and Safety of Sonrotoclax and Zanubrutinib for Adults with Relapsed or Refractory Mantle Cell Lymphoma

    Recruiting

    3 1
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • Zanubrutinib
    Austria France Germany Italy Poland Spain
Previous Page
1 2 3 4 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!